Prostate cancer
Conditions
Interventions
Sponsors
Radiation Oncology, Tokai University Hachioji Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)adenocaricnoma of the prostate which was pathologically confirmed 2) low risk group or intermediate risk group (T1-T2c and PSA =<20 ng/mL and Gleason score =<7) 3)neoadjuvant hormonal therapy for 3-12 months has been undertaken in patients with intermediate risk group 4)age:>=50,<80 years 5)Performance status:0-1 6)gold markers have been inserted 7)informed consent has been obtained
Exclusion criteria
Exclusion criteria: 1)Patients who have had any other cancer within the past 5 years 2)Patients who have uncontrollable diabetes mellitus 3)Patients who have serious comorbidities such as collagen disease, heart disease, interstitial pneumonia, liver cirrhosis 4)patients who have a psychological problem 5)patients who had previously received pelvic irradiation 6)patients who had previously received pelvic surgery 7)patients who had previously received TURP, orchiectomy, or HIFU 8)patients who had previously received chemotherapy for prostate cancer 9)patients who have Crohn's disease or ulcerative colitis 10)patients who require concomitant anticoagulant therapy 11)IPSS at registration>=20
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the incidence of delayed adverse events at 5 years | — |
Countries
Japan
Contacts
Public ContactAkitomo Sugawara
Tokai University Hachioji Hospital Radiation Oncology
Outcome results
None listed